Study of Axitinib and Temsirolimus in Solid Tumors
Completed · Phase 1
Conditions studied: Cancer
In brief
This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial.
Key facts
- Study ID
- NCT01529138
- Run by
- Emory University
- People needed
- 13
- Starts
- 2011-10-01
- Expected to finish
- 2014-03-01
- Last updated by the study team
- 2015-04-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Emory University Winship Cancer Institute — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.